High Net Worth Advisory Group’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
High Net Worth Advisory Group's CYTK Position: Q3 2026 in Review
High Net Worth Advisory Group held its Cytokinetics (CYTK) position steady in Q3 2026 at 5,000 shares worth $330K. The position accounts for 0.07% of the portfolio, ranked #200.
High Net Worth Advisory Group first reported a position in CYTK in Q4 2021 and has held it in 16 quarters since. The position peaked at $426K in Q2 2026. 473 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.
- High Net Worth Advisory Group held 5,000 shares of Cytokinetics worth $330K as of Q3 2026.
- High Net Worth Advisory Group left its Cytokinetics share count unchanged in Q3 2026.
- Cytokinetics made up 0.07% of High Net Worth Advisory Group's portfolio in Q3 2026, its #200 holding.
- High Net Worth Advisory Group first reported a position in Cytokinetics in Q4 2021 and has held it in 16 quarters since.
- High Net Worth Advisory Group's Cytokinetics position peaked at $426K in Q2 2026.
- 473 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.
Based on High Net Worth Advisory Group's 13F filing for Q3 2026, filed 26 Oct 2026.